Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$81.67 +1.0%	$82.85	$57.52 ▼ $93.25	$31.73B	1.43	3.87 million shs	3.58 million shs
HIMS Hims & Hers Health	$43.48 +3.1%	$52.18	$13.47 ▼ $72.98	$9.53B	2.08	37.02 million shs	24.53 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	+0.95%	+2.14%	-2.81%	-3.73%	+12.11%
HIMS Hims & Hers Health	+3.08%	-10.06%	-8.78%	-18.86%	+162.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXCM DexCom	4.8337 of 5 stars	3.5	4.0	0.0	4.7	3.5	2.5	1.9
HIMS Hims & Hers Health	2.7895 of 5 stars	2.0	3.0	0.0	0.0	3.0	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.95	Moderate Buy	$99.89	22.32% Upside
HIMS Hims & Hers Health	1.92	Reduce	$38.92	-10.48% Downside

Current Analyst Ratings Breakdown

Latest DXCM and HIMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	HIMS Hims & Hers Health	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$48.00 ➝ $37.00
8/5/2025	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/1/2025	DXCM DexCom	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$106.00
7/31/2025	DXCM DexCom	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2025	DXCM DexCom	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
7/31/2025	DXCM DexCom	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$99.00 ➝ $102.00
7/31/2025	DXCM DexCom	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$95.00 ➝ $102.00
7/31/2025	DXCM DexCom	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $106.00
7/30/2025	DXCM DexCom	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$93.00 ➝ $98.00
7/17/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$45.00 ➝ $48.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.03B	7.94	$2.27 per share	35.99	$6.56 per share	12.45
HIMS Hims & Hers Health	$1.48B	6.66	$0.36 per share	119.77	$2.49 per share	17.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.44	56.72	33.20	1.70	13.29%	30.41%	10.08%	10/23/2025 (Estimated)
HIMS Hims & Hers Health	$126.04M	$0.80	54.34	83.61	2.85	9.63%	26.26%	13.06%	11/3/2025 (Estimated)

Latest DXCM and HIMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/4/2025	Q2 2025	HIMS Hims & Hers Health	$0.18	$0.17	-$0.01	$0.17	$550.06 million	$544.83 million
7/30/2025	Q2 2025	DXCM DexCom	$0.45	$0.48	+$0.03	$0.45	$1.13 billion	$1.16 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.48	1.52	1.35
HIMS Hims & Hers Health	1.72	4.98	4.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
HIMS Hims & Hers Health	63.52%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
HIMS Hims & Hers Health	13.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	10,300	392.15 million	390.90 million	Optionable
HIMS Hims & Hers Health	1,637	226.02 million	195.03 million	Optionable

DXCM and HIMS Headlines

Recent News About These Companies

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm

2 hours ago | prnewswire.com

Insider Selling: Hims & Hers Health (NYSE:HIMS) CEO Sells 128,127 Shares of Stock

4 hours ago | marketbeat.com

Hims & Hers Health (NYSE:HIMS) Stock Price Down 5% After Analyst Downgrade

August 21 at 2:26 AM | americanbankingnews.com

HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS

August 20 at 10:31 PM | globenewswire.com

Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

August 20 at 4:45 PM | prnewswire.com

HIMS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 20 at 4:00 PM | globenewswire.com

Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - Hagens Berman

August 20 at 3:35 PM | globenewswire.com

Hims & Hers Health Inc. (NYSE: HIMS) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit

August 20 at 2:03 PM | prnewswire.com

INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HIMS

August 20 at 11:40 AM | globenewswire.com

Hims & Hers Health (NYSE:HIMS) Shares Down 5% After Analyst Downgrade

August 20 at 11:17 AM | marketbeat.com

HIMS Investors Have the Opportunity to Lead the Hims & Hers Health Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

August 20 at 10:05 AM | globenewswire.com

Here's How I Am Buying Hims & Hers At $37 Or Earning 4.2% Monthly Instead

August 20 at 5:01 AM | seekingalpha.com

Fox Run Management L.L.C. Acquires New Position in Hims & Hers Health, Inc. $HIMS

August 20 at 4:16 AM | marketbeat.com

Truist Financial Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $37.00

August 20 at 2:55 AM | americanbankingnews.com

Why Hims & Hers Health (HIMS) Stock Is Falling Today

August 20 at 2:12 AM | msn.com

Hims & Hers Health (NYSE:HIMS) Shares Down 2.3% on Analyst Downgrade

August 20 at 2:35 AM | americanbankingnews.com

Truist Cuts Hims & Hers Health, Inc. (HIMS) Price Target, Cites Mixed Revenue Outlook

August 20 at 2:30 AM | insidermonkey.com

HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS

August 19 at 9:24 PM | globenewswire.com

Hims & Hers Health, Inc.: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.

August 19 at 4:54 PM | globenewswire.com

Shareholders that lost money on Hims & Hers Health, Inc.(HIMS) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

August 19 at 4:09 PM | globenewswire.com

HIMS Deadline in 6 Days: Kessler Topaz Meltzer & Check, LLP Reminds Hims & Hers Health, Inc. (HIMS) Investors of Filing Deadline in Class Action Lawsuit

August 19 at 2:16 PM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DXCM and HIMS Company Descriptions

DexCom NASDAQ:DXCM

$81.67 +0.77 (+0.95%)

Closing price 08/20/2025 04:00 PM Eastern

Extended Trading

$81.53 -0.14 (-0.18%)

As of 07:58 AM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Hims & Hers Health NYSE:HIMS

$43.48 +1.30 (+3.07%)

Closing price 08/20/2025 03:59 PM Eastern

Extended Trading

$43.50 +0.02 (+0.06%)

As of 07:58 AM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time